Skip to main content

Table 4 Activity of fotemustine according to line of chemotherapy and histotype

From: Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation

 

Activity in 2nd line

no. pts (%)

(histotype)

Activity in 3rdline

no. pts (%)

(histotype)

Total pts

Partial Response

5 (16.5%)

(1 GBM, 2 AA, 2 AOD)

3 (30%)

(1 AA, 2 AOD)

8

Stable Disease

9 (30%)

(3 GBM, 4 AA, 1 AOA, 1 AOD)

2 (20%)

(1 GBM, 1 AOA)

11

Progression

16 (53.5%)

(7 GBM, 3 AA, 4 AOA, 2 AOD)

5 (50%)

(2 GBM, 1 AA, 1 AOA, 1 AOD)

21

Total pts

30

10

40

  1. AA, anaplastic astrocytoma; AOA, anaplastic oligoastrocytoma, AOD, anaplastic oligodendroglioma; GBM, glioblastoma multiforme; no., number; pts, patients